Actively Recruiting
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
Led by Novartis Pharmaceuticals · Updated on 2026-04-02
14000
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of sufficient evidence for ribociclib as a most recently marketed drug in the real-world setting.
CONDITIONS
Official Title
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hormone receptor-positive (ER+ or PR+) and HER2-negative advanced or metastatic breast cancer
- Started first-line anti-cancer treatment between January 1, 2024, and January 1, 2027
- Aged 18 years or older at the start of first-line treatment
- Have at least 3 months of follow-up medical records after beginning first-line treatment
You will not qualify if you...
- Diagnosed with any other invasive malignancy (except non-invasive or benign tumors) within 5 years before the breast cancer diagnosis
- Diagnosed with a new invasive malignancy at another site on the day of or within 3 months after the breast cancer diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative SIte
Bingjie, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here